ABT
ABT
Below: live stock price for ABT (ABT), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
ABT (ABT) is a Healthcare company based in United States. Operating in Medical Devices, it employs about 122,000 people. Over the past year ABT traded between 81.97 and 133.34 USD. It currently yields 2.53% in dividends.
- Prev close
- $98.49
- Volume (24h)
- —
- Market cap
- —
- Currency
- USD
Score
41/ 100 · Weak
- Value43
- Quality58
- Momentum17
- Growth24
- Risk79
- Dividend37
- Liquidity27
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 99.1548 -0.45%
- +20 bars
- 98.5438 -1.06%
- +60 bars
- 98.3084 -1.30%
- +120 bars
- 98.2998 -1.31%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.046 USD.
Interpretation
Composite signals look weak. Strength: risk profile with weakness: momentum. Price sits near the lower third of the recent range, trend is sloping downward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value43/100
Value looks weak — driven by P/E (32.84).
P/E:32.84P/B:3.45PEG:1.83 - Quality58/100
Quality looks mixed — driven by Gross margin (56.85%).
ROE:10.58%ROA:5.33%Profit margin:11.65%Gross margin:56.85% - Momentum17/100
Momentum looks fragile — driven by 52w change (-24.19%).
52w change:-24.19% - Growth24/100
Growth looks fragile — driven by Earnings growth (-47.50%).
Revenue growth:13.00%Earnings growth:-47.50% - Risk79/100
Risk looks strong — driven by Debt / equity (63.21).
Beta:0.58Debt / equity:63.21Short interest:0.88% - Dividend37/100
Dividend looks weak — driven by Payout ratio (78.71%).
Dividend yield:2.53%Payout ratio:78.71% - Liquidity27/100
Liquidity looks fragile — driven by Current ratio (1.38).
Current ratio:1.38Quick ratio:0.8
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 250 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 27.3%
- Max drawdown
- -38.1%
- Below period high
- -25.3%
- Best day
- +10.71%
- Worst day
- -10.04%
- Up days
- 47%
- Current streak
- 1 up
- Typical day swing
- 2.2%
- Volume vs average
- -14%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 117.34 high → 95.06 low · 60 bars
- ResistanceFib +161.8% extensionnot reached153.389 USD+54.01% from current
- ResistanceFib +100% extensionnot reached139.62 USD+40.18% from current
- ResistanceFib +61.8% extensionnot reached131.109 USD+31.64% from current
- ResistanceFib +27.2% extensionnot reached123.4002 USD+23.90% from current
- ResistanceFib 23.6% retracementtested 6×112.0819 USD+12.53% from current
- ResistanceFib 38.2% retracementtested 9×108.829 USD+9.27% from current
- ResistanceFib 50% midpointtested 8×106.2 USD+6.63% from current
- ResistanceFib 61.8% retracementtested 9×103.571 USD+3.99% from current
- ResistanceFib 78.6% retracementNearesttested 7×99.8279 USD+0.23% from current
- Current99.6 USD
- SupportFib −27.2% extensionnot reached88.9998 USD-10.64% from current
- SupportFib −61.8% extensionnot reached81.291 USD-18.38% from current
- SupportFib −100% extensionnot reached72.78 USD-26.93% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $133.34
- 52w low
- $81.97
- 52w change
- -24.19%
- Day high
- $101.82
- Day low
- $99.78
- P/E (TTM)
- 32.84
- Forward P/E
- 16.79
- PEG
- 1.83
- Price / Book
- 3.45
- Beta (5Y)
- 0.58
- Enterprise value
- 200.12B
- EV / Revenue
- 4.3
- EV / EBITDA
- 17.13
- EPS (TTM)
- $3.10
- Forward EPS
- $6.06
- Dividend yield
- 2.53%
- Dividend rate
- $2.52
- Payout ratio
- 78.71%
- Revenue (TTM)
- 46.58B
- EBITDA
- 11.68B
- Free cash flow
- 7.21B
- Total cash
- 5.6B
- Total debt
- 32.72B
- Debt / Equity
- 63.21
- Current ratio
- 1.38
- Quick ratio
- 0.8
- Profit margin
- 11.65%
- Gross margin
- 56.85%
- Return on assets
- 5.33%
- Return on equity
- 10.58%
- Shares outstanding
- 1.74B
- Float
- 1.72B
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.58
- less volatile
- 52-week change
- -24.19%
- Short % of float
- 0.88%
- Short ratio (days)
- 1.57
- Debt / Equity
- 63.21
- very high leverage
- Current ratio
- 1.38
- Quick ratio
- 0.8
- ROE
- 10.58%
- ROA
- 5.33%
- PEG ratio
- 1.83
- fair
- EV / Revenue
- 4.3
- EV / EBITDA
- 17.13
- Revenue growth
- 13.00%
- Earnings growth
- -47.50%
- EBITDA
- 11.68B
- Free cash flow
- 7.21B
- Total cash
- 5.6B
- Total debt
- 32.72B
- Insider holdings
- 0.49%
- Institutional
- 81.79%
Recent rating changes
- 2026-10-07BarclaysOverweightinit
- 2026-10-02Rothschild & CoNeutral → Buyup
- 2026-09-08TD CowenBuy → Buyreit
- 2026-08-25TD CowenBuy → Buymain
- 2026-08-21TD CowenBuy → Buymain
- 2026-08-14CitigroupBuy → Buymain
- 2026-08-13Wolfe ResearchPeer Perform → Outperformup
- 2026-07-28UBSBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-08-20
- Periodic Financial Reports10-Q2026-07-28
- Corporate Changes & Voting Matters8-K2026-07-16
- Annual report of employee stock purchase11-K2026-06-18
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Periodic Financial Reports10-Q2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-27
- Offering RegistrationsS-82026-04-24
- Corporate Changes & Voting Matters8-K2026-04-17
- Corporate Changes & Voting Matters8-K2026-04-16
- Offering RegistrationsS-82026-03-23
- Proxy StatementsDEFA14A2026-03-13
Recent news
- Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool1h ago
- Ascensia leads $36M funding round for glucose sensor startupMedTech Dive2h ago
- Has Medtronic Stock Become A Different Bet?Trefis3h ago
- Abbott Laboratories is More than a Dividend Stock. Here’s Why.Insider Monkey1d ago
- AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.Motley Fool1d ago
- Abbott Laboratories (ABT) Debuts Ensure Max Protein Powder With Creatine And HMBSimply Wall St.1d ago
- History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.Motley Fool2d ago
- Abbott (ABT) Stock Could Be 24% Overvalued After Heart Failure NewsSimply Wall St.2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,462 USD-1.20%
- 7203.TToyota Motor Corporation2,910.5 USD+0.29%
- 9984.TSoftBank Group Corp.5,803 USD-3.92%
- 6758.TSony Group Corporation3,814 USD+2.91%
- 6861.TKeyence Corporation80,540 USD+0.68%
- NVDANVIDIA Corporation226.32 USD-1.29%
- AAPLApple Inc.340.97 USD+1.29%
- GOOGLAlphabet Inc.352.72 USD+0.30%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.